| 1 | Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial | 22.5 | 30 | Citations (PDF) |
| 2 | Perspectives on the role of “-Omics” in predicting response to immunotherapy | 4.9 | 3 | Citations (PDF) |
| 3 | Approaches to overcome the current treatment plateau in immunotherapy | 4.9 | 3 | Citations (PDF) |
| 4 | The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? | 4.9 | 11 | Citations (PDF) |
| 5 | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream | 4.9 | 12 | Citations (PDF) |
| 6 | Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers? 2024, 256, 108613 | | 61 | Citations (PDF) |
| 7 | Immunotherapy in cutaneous melanoma and biologics in psoriatic disease: similarities and differences from a clinical multidisciplinary perspective | 3.0 | 3 | Citations (PDF) |
| 8 | Improving Influenza Vaccination Coverage in Patients with Cancer: A Position Paper from a Multidisciplinary Expert Group | 2.9 | 2 | Citations (PDF) |
| 9 | Immunotherapy for brain metastases and primary brain tumors | 4.9 | 22 | Citations (PDF) |
| 10 | Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID | 3.2 | 0 | Citations (PDF) |
| 11 | From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma | 2.7 | 3 | Citations (PDF) |
| 12 | Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade | 2.8 | 16 | Citations (PDF) |
| 13 | Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial | 13.7 | 37 | Citations (PDF) |
| 14 | The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma | 4.1 | 22 | Citations (PDF) |
| 15 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma | 16.9 | 1,048 | Citations (PDF) |
| 16 | KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation | 4.9 | 9 | Citations (PDF) |
| 17 | First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers | 2.1 | 24 | Citations (PDF) |
| 18 | Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study | 4.9 | 8 | Citations (PDF) |
| 19 | SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines | 4.9 | 4 | Citations (PDF) |
| 20 | Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” | 2.7 | 6 | Citations (PDF) |
| 21 | Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 2021, 9, e001167 | | 14 | Citations (PDF) |
| 22 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial | 27.4 | 67 | Citations (PDF) |
| 23 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial | 27.4 | 362 | Citations (PDF) |
| 24 | Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases | 6.8 | 66 | Citations (PDF) |
| 25 | Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now! | 4.9 | 27 | Citations (PDF) |
| 26 | Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study | 23.3 | 43 | Citations (PDF) |
| 27 | Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix | 4.9 | 8 | Citations (PDF) |
| 28 | COVID and Lung Cancer | 4.2 | 35 | Citations (PDF) |
| 29 | Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy | 3.1 | 8 | Citations (PDF) |
| 30 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial | 27.4 | 489 | Citations (PDF) |
| 31 | SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome | 4.9 | 21 | Citations (PDF) |
| 32 | Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma 2020, 8, e000391 | | 57 | Citations (PDF) |
| 33 | Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival | 3.8 | 24 | Citations (PDF) |
| 34 | Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy | 2.0 | 13 | Citations (PDF) |
| 35 | Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy | 8.5 | 16 | Citations (PDF) |
| 36 | Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial | 4.9 | 168 | Citations (PDF) |
| 37 | Immunotherapy of brain metastases: breaking a “dogma” | 11.3 | 88 | Citations (PDF) |
| 38 | Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172) | 4.9 | 42 | Citations (PDF) |
| 39 | Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) | 4.9 | 90 | Citations (PDF) |
| 40 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | 34.5 | 3,420 | Citations (PDF) |
| 41 | NK‐ and T‐cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti‐CTLA‐4 therapy | 4.3 | 38 | Citations (PDF) |
| 42 | Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with
BRAF
V600-mutated Metastatic Melanoma | 6.8 | 37 | Citations (PDF) |
| 43 | Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial | 6.8 | 77 | Citations (PDF) |
| 44 | Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial | 27.4 | 217 | Citations (PDF) |
| 45 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma | 34.5 | 1,853 | Citations (PDF) |
| 46 | Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma | 5.5 | 23 | Citations (PDF) |
| 47 | New horizons from immunotherapy in malignant pleural mesothelioma | 1.2 | 8 | Citations (PDF) |
| 48 | Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy | 3.8 | 35 | Citations (PDF) |
| 49 | Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study | 23.3 | 208 | Citations (PDF) |
| 50 | Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge | 4.6 | 4 | Citations (PDF) |
| 51 | Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy | 3.0 | 21 | Citations (PDF) |
| 52 | International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study | 62.1 | 1,919 | Citations (PDF) |
| 53 | The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology | 4.6 | 1 | Citations (PDF) |
| 54 | Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial | 27.4 | 105 | Citations (PDF) |
| 55 | Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients | 4.9 | 111 | Citations (PDF) |
| 56 | Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab | 2.5 | 41 | Citations (PDF) |
| 57 | Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial | 27.4 | 489 | Citations (PDF) |
| 58 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | 34.5 | 2,136 | Citations (PDF) |
| 59 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | 34.5 | 4,209 | Citations (PDF) |
| 60 | Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial | 27.4 | 408 | Citations (PDF) |
| 61 | Immunotherapy targeting immune check-point(s) in brain metastases | 10.5 | 9 | Citations (PDF) |
| 62 | Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences | 10.5 | 8 | Citations (PDF) |
| 63 | Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT) | 10.5 | 1 | Citations (PDF) |
| 64 | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody | 6.8 | 380 | Citations (PDF) |
| 65 | Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab | 6.8 | 562 | Citations (PDF) |
| 66 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy | 34.5 | 1,285 | Citations (PDF) |
| 67 | Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study | 5.4 | 22 | Citations (PDF) |
| 68 | Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab | 6.8 | 514 | Citations (PDF) |
| 69 | Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma | 10.6 | 76 | Citations (PDF) |
| 70 | Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy | 2.9 | 14 | Citations (PDF) |
| 71 | The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival | 1.9 | 26 | Citations (PDF) |
| 72 | Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study | 4.6 | 179 | Citations (PDF) |
| 73 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | 34.5 | 7,743 | Citations (PDF) |
| 74 | A phase II study combining tremelimumab and durvalumab (MEDI4736) immunomodulating antibodies in mesothelioma patients: The NIBIT-MESO-1 study | 9.9 | 2 | Citations (PDF) |
| 75 | Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies | 1.9 | 70 | Citations (PDF) |
| 76 | Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 | 12.4 | 159 | Citations (PDF) |
| 77 | Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study | 9.9 | 124 | Citations (PDF) |
| 78 | Nivolumab in Previously Untreated Melanoma without
BRAF
Mutation | 34.5 | 5,360 | Citations (PDF) |
| 79 | Immune Checkpoint Blockade in Malignant Mesothelioma | 1.9 | 8 | Citations (PDF) |
| 80 | Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study | 23.3 | 198 | Citations (PDF) |
| 81 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | 27.4 | 2,584 | Citations (PDF) |
| 82 | Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial | 27.4 | 1,207 | Citations (PDF) |
| 83 | Epigenetics Meets Immune Checkpoints | 1.9 | 32 | Citations (PDF) |
| 84 | Vemurafenib in
BRAF
V600 Mutated Metastatic Melanoma: A Subanalysis of the Italian Population of a Global Safety Study | 2.3 | 8 | Citations (PDF) |
| 85 | Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models | 5.4 | 68 | Citations (PDF) |
| 86 | Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy | 6.8 | 99 | Citations (PDF) |
| 87 | Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program | 1.6 | 96 | Citations (PDF) |
| 88 | Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells | 6.8 | 243 | Citations (PDF) |
| 89 | Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology | 2.3 | 4 | Citations (PDF) |
| 90 | Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma | 9.5 | 190 | Citations (PDF) |
| 91 | A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma | 4.0 | 25 | Citations (PDF) |
| 92 | Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma | 6.8 | 39 | Citations (PDF) |
| 93 | Vemurafenib in Brafv600 Mutated Metastatic Melanoma (Mm): a Subanalysis of the Italian Population of a Global Safety Study | 9.9 | 4 | Citations (PDF) |
| 94 | Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases | 2.5 | 113 | Citations (PDF) |
| 95 | Epigenetic drugs as immunomodulators for combination therapies in solid tumors 2014, 142, 339-350 | | 98 | Citations (PDF) |
| 96 | Combined Vemurafenib and Cobimetinib in
BRAF
-Mutated Melanoma | 34.5 | 2,048 | Citations (PDF) |
| 97 | Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme | 11.3 | 103 | Citations (PDF) |
| 98 | Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours | 4.9 | 1,306 | Citations (PDF) |
| 99 | Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort | 6.4 | 156 | Citations (PDF) |
| 100 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study | 27.4 | 951 | Citations (PDF) |
| 101 | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | 27.4 | 1,446 | Citations (PDF) |
| 102 | Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma | 4.9 | 167 | Citations (PDF) |
| 103 | CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? | 4.6 | 18 | Citations (PDF) |
| 104 | Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response | 4.6 | 34 | Citations (PDF) |
| 105 | Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma | 6.4 | 32 | Citations (PDF) |
| 106 | Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme | 4.6 | 128 | Citations (PDF) |
| 107 | Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial | 27.4 | 348 | Citations (PDF) |
| 108 | Update on the role of ipilimumab in melanoma and first data on new combination therapies | 2.1 | 28 | Citations (PDF) |
| 109 | Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials | 9.9 | 157 | Citations (PDF) |
| 110 | Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes | 4.3 | 20 | Citations (PDF) |
| 111 | Epigenetics of Melanoma: Implications for Immune-Based Therapies | 1.9 | 19 | Citations (PDF) |
| 112 | Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme | 11.3 | 23 | Citations (PDF) |
| 113 | Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications | 5.5 | 22 | Citations (PDF) |
| 114 | Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I–Modified Peptides | 6.8 | 67 | Citations (PDF) |
| 115 | Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients | 6.4 | 54 | Citations (PDF) |
| 116 | Cancer classification using the Immunoscore: a worldwide task force | 6.4 | 742 | Citations (PDF) |
| 117 | The role of BRAF V600 mutation in melanoma | 6.4 | 727 | Citations (PDF) |
| 118 | Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond | 4.0 | 15 | Citations (PDF) |
| 119 | Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial | 27.4 | 282 | Citations (PDF) |
| 120 | The cost of unresectable stage III or stage IV melanoma in Italy | 11.3 | 27 | Citations (PDF) |
| 121 | Four-Year Survival Update for Metastatic Melanoma (MM) Patients (PTS) Treated with Ipilimumab (IPI) + Dacarbazine (DTIC) on Phase 3 Study CA184-024 | 9.9 | 7 | Citations (PDF) |
| 122 | Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program | 9.9 | 0 | Citations (PDF) |
| 123 | Five-Year Survival Rates for Patients (PTS) with Metastatic Melanoma (MM) Treated with Ipilimumab (IPI) in Phase II Trials | 9.9 | 13 | Citations (PDF) |
| 124 | Efficacy and Safety of Ipilimumab in Patients with Pretreated, Mucosal Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP) | 9.9 | 5 | Citations (PDF) |
| 125 | Immunomodulatory activity of SGI-110, a 5-aza-2′-deoxycytidine-containing demethylating dinucleotide | 4.6 | 67 | Citations (PDF) |
| 126 | Efficacy and Safety of Ipilimumab in Patients with Pretreated, Ocular Melanoma: Experience from Italian Clinics Participating in the European Expanded Access Programme (EAP) | 9.9 | 2 | Citations (PDF) |
| 127 | Long Term Survival and Immunological Correlates in Metastatic Melanoma Treated with Ipilimumab at 10 Mgs within an Expanded Access Program | 9.9 | 4 | Citations (PDF) |
| 128 | The biology of cancer testis antigens: Putative function, regulation and therapeutic potential | 4.1 | 349 | Citations (PDF) |
| 129 | Defining the critical hurdles in cancer immunotherapy | 6.4 | 149 | Citations (PDF) |
| 130 | Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma | 34.5 | 4,328 | Citations (PDF) |
| 131 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation | 34.5 | 7,454 | Citations (PDF) |
| 132 | Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6
th
-7
th
2010" | 6.4 | 30 | Citations (PDF) |
| 133 | Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients | 6.4 | 55 | Citations (PDF) |
| 134 | Expression and regulation of B7‐H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications | 4.1 | 19 | Citations (PDF) |
| 135 | Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success? | 5.5 | 14 | Citations (PDF) |
| 136 | Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy | 4.6 | 130 | Citations (PDF) |
| 137 | CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893 | 2.3 | 21 | Citations (PDF) |
| 138 | Biology and Clinical Applications of CD40 in Cancer Treatment | 1.9 | 43 | Citations (PDF) |
| 139 | Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications | 1.9 | 52 | Citations (PDF) |
| 140 | The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications | 1.9 | 235 | Citations (PDF) |
| 141 | Anti–CTLA-4 Antibody Adjuvant Therapy in Melanoma | 1.9 | 38 | Citations (PDF) |
| 142 | Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy | 1.9 | 34 | Citations (PDF) |
| 143 | Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma | 4.1 | 21 | Citations (PDF) |
| 144 | CXCR6, a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal, Identifies More Aggressive Human Melanoma Cancer Stem Cells | 2.3 | 67 | Citations (PDF) |
| 145 | Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours | 5.5 | 153 | Citations (PDF) |
| 146 | Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies | 6.4 | 100 | Citations (PDF) |
| 147 | Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) | 4.6 | 80 | Citations (PDF) |
| 148 | High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients | 2.3 | 903 | Citations (PDF) |
| 149 | Epigenetically regulated tumor-associated antigens in melanoma | 0.4 | 1 | Citations (PDF) |
| 150 | Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria | 6.8 | 3,057 | Citations (PDF) |
| 151 | Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases | 4.6 | 279 | Citations (PDF) |
| 152 | Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology | 6.4 | 43 | Citations (PDF) |
| 153 | Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention | 4.6 | 5 | Citations (PDF) |
| 154 | Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status | 4.1 | 57 | Citations (PDF) |
| 155 | The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward | 6.4 | 2 | Citations (PDF) |
| 156 | A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" | 6.4 | 46 | Citations (PDF) |
| 157 | The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level | 1.4 | 3 | Citations (PDF) |
| 158 | 5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story | 3.8 | 21 | Citations (PDF) |
| 159 | Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications | 4.1 | 130 | Citations (PDF) |
| 160 | Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications | 4.1 | 52 | Citations (PDF) |
| 161 | Is it the primetime for endoglin (CD105) in the clinical setting? | 5.5 | 12 | Citations (PDF) |
| 162 | Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy | 1.9 | 45 | Citations (PDF) |
| 163 | Epigenetic Immunomodulation of Hematopoietic Malignancies | 1.9 | 18 | Citations (PDF) |
| 164 | Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications | 4.1 | 23 | Citations (PDF) |
| 165 | A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients | 4.6 | 139 | Citations (PDF) |
| 166 | Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma | 4.1 | 7 | Citations (PDF) |
| 167 | Title is missing! | 6.4 | 152 | Citations (PDF) |
| 168 | Title is missing! | 6.4 | 4 | Citations (PDF) |
| 169 | Methylation-regulated expression of HLA class I antigens in melanoma | 4.3 | 44 | Citations (PDF) |
| 170 | Differential levels of soluble endoglin (CD105) in myeloid malignancies | 4.1 | 48 | Citations (PDF) |
| 171 | Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels | 6.5 | 230 | Citations (PDF) |
| 172 | Epigenetic targets for immune intervention in human malignancies | 6.5 | 68 | Citations (PDF) |
| 173 | Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach? | 6.5 | 47 | Citations (PDF) |
| 174 | Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1 | 4.0 | 62 | Citations (PDF) |
| 175 | Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer | 4.6 | 122 | Citations (PDF) |
| 176 | Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications | 5.5 | 86 | Citations (PDF) |
| 177 | Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma | 2.3 | 112 | Citations (PDF) |
| 178 | European approach to antibody-based immunotherapy of melanoma | 1.9 | 3 | Citations (PDF) |
| 179 | Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells* | 4.1 | 7 | Citations (PDF) |
| 180 | Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells | 4.6 | 39 | Citations (PDF) |
| 181 | Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies | 5.8 | 6 | Citations (PDF) |
| 182 | Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-? | 4.3 | 10 | Citations (PDF) |
| 183 | Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies | 4.1 | 167 | Citations (PDF) |
| 184 | Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement | 4.1 | 29 | Citations (PDF) |
| 185 | Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells | 3.2 | 61 | Citations (PDF) |
| 186 | Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions | 2.3 | 19 | Citations (PDF) |
| 187 | In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells | 4.6 | 9 | Citations (PDF) |
| 188 | The overlooked ?nonclassical? functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells | 4.1 | 19 | Citations (PDF) |
| 189 | Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR) | 2.3 | 124 | Citations (PDF) |
| 190 | Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA-A3.1 melanoma patients | 3.1 | 18 | Citations (PDF) |
| 191 | Pregnancy and Malignant Neoplasms of the Head and Neck | 1.4 | 24 | Citations (PDF) |
| 192 | Structure, distribution, and functional role of protectin (CD59) in complement-susceptibility and in immunotherapy of human malignancies (Review). | 3.8 | 16 | Citations (PDF) |
| 193 | BIPHASIC CONTROL OF NF-κB ACTIVATION INDUCED BY THE TRIGGERING OF HLA-DR ANTIGENS EXPRESSED ON B CELLS | 3.5 | 4 | Citations (PDF) |
| 194 | Tumour-derived interleukin 1α (IL-1α) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells | 5.5 | 26 | Citations (PDF) |
| 195 | Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability | 4.6 | 68 | Citations (PDF) |
| 196 | Melanoma immunotherapy: new dreams or solid hopes? | 6.9 | 15 | Citations (PDF) |
| 197 | Triggering of Target of an Antiproliferative Antibody‐1 (TAPA‐1/CD81) Up‐Regulates the Release of Tumour Necrosis Factor‐α by the EBV‐B Lymphoblastoid Cell Line JY | 1.3 | 21 | Citations (PDF) |
| 198 | Letters to the Editor | 1.3 | 0 | Citations (PDF) |
| 199 | Expression and structural features of endoglin (CD105), a transforming growth factor β1 and β3 binding protein, in human melanoma | 5.5 | 63 | Citations (PDF) |
| 200 | Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells | 3.2 | 86 | Citations (PDF) |
| 201 | Melanoma-Associated Hypopigmentation: Where Are the Antibodies? | 1.3 | 20 | Citations (PDF) |
| 202 | Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. | 0.6 | 37 | Citations (PDF) |
| 203 | Circulating Intercellular Adhesion Molecule 1 as a Marker of Disease Progression in Cutaneous Melanoma | 34.5 | 30 | Citations (PDF) |
| 204 | Expression and Functional Role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on Human Blood Cells | 1.4 | 34 | Citations (PDF) |
| 205 | Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. | 10.6 | 61 | Citations (PDF) |
| 206 | Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders | 4.8 | 86 | Citations (PDF) |
| 207 | Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10 | 4.6 | 8 | Citations (PDF) |
| 208 | Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells | 4.3 | 28 | Citations (PDF) |
| 209 | Heterogeneity in the mitogenic response of peripheral blood mononuclear cells to a pan T monoclonal antibody | 0.6 | 4 | Citations (PDF) |
| 210 | HLA and prognostic factors in primary breast cancer | 4.3 | 12 | Citations (PDF) |
| 211 | The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy | 4.0 | 3 | Citations (PDF) |
| 212 | Strong association between an HLA‐DR antigen and thyroid carcinoma | 0.6 | 45 | Citations (PDF) |
| 213 | Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients | 5.4 | 49 | Citations (PDF) |
| 214 | Title is missing! 0 | | 1 | Citations (PDF) |
